[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-thromboembolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-thromboembolism":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,47,78,114,137,164,189,220,243,275,299,326,350,373,398,418,443,469,491,519,546,575,600,627,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100493189","defiance-rct-of-clottriever-system-versus-anticoagulation-in-deep-vein-thrombosis-100493189",false,"NCT05701917","DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis","DEFIANCE","Inclusion Criteria\n\n* Age ≥ 18 years\n* Proximal lower extremity unilateral DVT involving at least the common femoral, external iliac, or common iliac veins, alone or in combination\n* Symptom onset within 12 weeks of enrollment in the study\n* Significant symptoms, as defined by a Villalta score \\> 9\n* Willing and able to provide informed consent\n\nExclusion Criteria\n\n* Bilateral iliofemoral DVT\n* Prior venous stent in the target venous segment\n* IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n* IVC filter in place at the time of enrollment\n* Limb-threatening circulatory compromise (e.g., phlegmasia)\n* Clot in transit including IVC thrombus presenting as extension of \\>2cm into the IVC from the CIV\n* Symptomatic PE with right heart strain where the physician judges that a DVT intervention is inappropriate at this time.\n* Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement\n* Severe allergy, hypersensitivity to, or thrombocytopenia from heparin\n* Severe allergy to iodinated contrast agents that cannot be mitigated\n* Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 1.7 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment\n* Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis\n* Inability to provide therapeutic anticoagulation per Investigator discretion\n* Uncontrolled severe hypertension on repeated readings (systolic \\> 180mmHg or diastolic \\> 105mmHg)\n* Recently (\\\u003C 30 days) had DVT interventional procedure\n* Subject is participating in another study that may interfere with this study\n* Life expectancy \\\u003C 6 months or chronic non-ambulatory status\n* Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n* Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of ClotTriever per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)\n* Subject has previously completed or withdrawn from this study\n* Patient unwilling or unable to conduct the follow up visits per protocol","ALL","18 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.",[28,29,30],"Venous Thromboembolism","Deep Venous Thrombosis","Post-Thrombotic Syndrome",[28,29,30,32,33],"Anticoagulation","Percutaneous Mechanical Thrombectomy","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2023-01-06",{"date":42,"type":22},"2027-01-15",{"name":44,"class":45},"Inari Medical","INDUSTRY",64,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100619890","aspiration-thrombectomy-using-the-symphony-or-prodigy-system-100619890","NCT07350499","Aspiration Thrombectomy Using the Symphony or Prodigy System","Long-Term CLinical Evaluation of Aspiration ThRombectomy Using the Symphony or ProdIgy Thrombectomy System - CLEAR-IT","CLEAR-IT","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject is willing and able to comply with the follow-up schedule specified in this protocol\n3. Subject is willing and able to provide written informed consent prior to any study-related data collection\n4. Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use\n\nExclusion Criteria:\n\n1. Subjects with any contraindications per the applicable Instructions for Use\n2. Subject with life expectancy of less than 1 year\n3. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices\n4. Subject who may be unable to complete study follow-up\n5. Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging",{"count":56,"type":22},750,"OBSERVATIONAL","The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.",[60,28,61],"Arterial Thromboembolism","Pulmonary Embolism",[61,63,64,65,66,32,67],"Thrombus","Thromboembolism","Aspiration","Aspiration thrombectomy","Peripheral vasculature","2026-06-23",{"date":70,"type":38},"2026-06-26",{"date":72,"type":38},"2026-02-13",{"date":74,"type":22},"2030-09",{"name":76,"class":45},"Imperative Care, Inc.",4,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111","NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria",{"count":87,"type":22},1424,[89],"PHASE3","Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[28,92,61,93,94,95],"Deep Vein Thrombosis","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[97,98,99,100,101,102],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","2026-06-22",{"date":105,"type":38},"2026-06-25",{"date":107,"type":38},"2024-07-19",{"date":109,"type":22},"2028-11-19",{"name":111,"class":112},"University Hospital, Angers","OTHER_GOV",37,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":77},"100508435","a-study-to-observe-the-pattern-of-use-and-safety-of-rivaroxaban-in-children-under-2-years-old-with-venous-thromboembolism-vte-100508435","NCT05900388","A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism","XAPAEDUS","Inclusion Criteria:\n\n* Evidence of initiation of an anticoagulant therapy (index drug), either rivaroxaban oral suspension or other anticoagulation therapies (heparins, Vitamin K antagonists (VKAs), other Direct oral anticoagulants (DOACs)). Initiation will be defined as a first record of any anticoagulation therapy (rivaroxaban or SOC) without any anticoagulation therapy in the previous 6 months, or since date of birth for children less than 6 months\n* Evidence of a prior VTE diagnosis (index VTE), defined as the presence of at least one primary\u002Fmain or secondary diagnosis code for VTE recorded in inpatient setting in the previous 30 days\n* Age less than two years on index date.\n* Baseline period for availability of patient data history in the data source. A minimal baseline period of six months before index date for children aged between six months and two years, and a baseline period since birth for children less than six months of age will be required.\n\nExclusion Criteria:\n\n\\- None","2 Years",{"count":124,"type":22},850,"This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).\n\nVTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.\n\nRivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.\n\nThe purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.\n\nThe main information that researchers will collect in this study:\n\n* Age, gender, and other information about the child and their illness\n* Type of VTE treatment given to the child\n* Occurrence of medically important bleeding and its severity\n\nFurther information that researchers will collect:\n\n* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE\n* Return of VTE symptoms\n* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.\n\nThe data for this study will be collected from electronic health records and health insurance claims data until 2026.\n\nResearchers will observe each child during treatment until:\n\n* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,\n* their information is no longer available, or\n* the study ends.",[28,127],"Children Under 2 Years","NOT_YET_RECRUITING","2026-06-18",{"date":103,"type":38},{"date":132,"type":22},"2026-09-01",{"date":134,"type":22},"2029-06-30",{"name":136,"class":45},"Bayer",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":18,"minAge":19,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100548256","variations-in-the-hemostatic-system-induced-by-a-standardized-walking-test-100548256","NCT06418633","Variations in the Hemostatic System Induced by a Standardized Walking Test","Variations in the Hemostatic System Induced by a Standardized Walking Test: Controls vs. Cases With a History of Non-anticoagulated Venous Thromboembolic Disease","FAST&THROMBIN","Inclusion Criteria:\n\n* Inclusion criteria common to both groups :\n* Patients who have given written informed consent.\n* Patients who are affiliated to or beneficiaries of a social security scheme.\n\nInclusion criteria specific to the Patient Group:\n\n* Patients with a personal history of provoked venous thromboembolism, venous thrombosis and\u002For pulmonary embolism, with the last attack dating back to more than 6 months, and whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.\n\nDefinition of provoked venous thromboembolism : The clinical criteria used to classify venous thromboembolism as provoked are :\n\n* First year of combined oestrogen-progestogen oral contraception, or contraception using an oestrogen-impregnated vaginal ring or transcutaneous synthetic oestrogen patch.\n* Hormonal stimulation for oocyte retrieval\n* Pregnancy and 6 weeks post-partum\n* Surgery\n* Trauma\n* Immobilisation in plaster or splint\n* Outbreak of acute infectious disease\n* Acute flare-up of inflammatory disease\n* Prolonged air travel lasting at least 4 hours\n* Prolonged strict bed rest lasting at least 3 consecutive days.\n\nInclusion criteria specific to the Control Group:\n\n* Subjects with no personal history of venous thromboembolism\n* Subjects with no family history of venous thromboembolism in first-degree relatives\n* Subjects of the same sex and age with a tolerance of +\u002F- 5 years in relation to the matched case.\n\nExclusion Criteria:\n\n* Patients who are physically unable to perform the 60-minute walking test, for any reason, in particular cardiovascular contraindications to exercise (recent acute coronary syndrome unstable angina, rhythm disorders, tight aortic stenosis, cardiac heart failure, acute myocarditis, pericarditis or endocarditis endocarditis, poorly controlled hypertension, pre-stress blood pressure \\> 200\u002F110 mmHg, recent stroke or transient ischemic attack).\n* Patients on anticoagulant or antithrombotic treatment, ongoing or discontinued within the last month.\n* Patients treated for pulmonary embolism who remain dyspneic after anticoagulant treatment and requiring a work-up for pulmonary hypertension.\n* Last surgery dating back to less than 3 months.\n* Known chronic morbidities: diabetes mellitus, chronic inflammatory or infectious disease, heart failure, renal insufficiency, hepatic insufficiency or arterial thrombosis dating back to less than 3 months.\n* For women: treatment containing synthetic or natural estrogen, in progress or discontinued for less than a month\n* Pregnancy within the last year.\n* Difficult venous access.\n* Regular practice of an intensive sporting\u002Fphysical activity, such as running, tennis, cycling etc. of more than 3 hours per week.",true,"65 Years",{"count":148,"type":22},94,[25],"Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without. Both groups will be subjected to a walking test and with electrocardiogram measurements and blood tests.",[28],[153],"Physical exercise","2026-06-17",{"date":103,"type":38},{"date":157,"type":38},"2025-02-11",{"date":159,"type":22},"2030-04-01",{"name":161,"class":162},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100544733","residual-pulmonary-vascular-obstruction-index-computed-with-ventilationperfusion-spectct-imaging-to-predict-the-risk-of-venous-thromboembolism-recurrence-in-patients-with-pulmonary-embolism-pronospect-100544733","NCT06372730","Residual Pulmonary Vascular Obstruction Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)","Residual Pulmonary Vascular Obstruction (RPVO) Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients With Pulmonary Embolism (PE)","PRONOSPECT","Inclusion Criteria:\n\n* Patients ≥ 18 years,\n* who experienced an objectively proven PE,\n* who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.\n\nExclusion Criteria:\n\n* Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)\n* Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research\n* No Social security affiliation\n* Isolated DVT\n* Pregnant women and parturients\n* Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)\n* Life expectancy \\\u003C 6 months\n* Any patients for whom there is a strong indication to treat longer than 6 months:\n\n  * PE provoked by a major persistent factor (e.g. cancer)\n  * Recurrent unprovoked PE\n\nPE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean section)\n\nAND none of the following persistent factors :\n\n* BMI ≥ 30\n* Chronic respiratory disease\n* Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.)\n* Hepatocellular insufficiency\n* Renal insufficiency with creatinine clearance \\\u003C 60 mL\u002Fmin\n* Chronic or persistent immobilization",{"count":173,"type":22},665,[25],"Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group.\n\nAnticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence.\n\nIdentifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation.\n\nIn 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan.\n\nIn patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images.\n\nVentilation\u002FPerfusion Single Photon Emission Computed Tomography (V\u002FQ SPECT\u002FCT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling more accurate and reproducible quantification of RPVO.\n\nThe main hypothesis of this study is that in patients with PE at intermediate risk of recurrence, RPVO computed with V\u002FQ SPECT\u002FCT imaging may be an important predictor of recurrence.",[61,28],[178],"venous thromboembolism recurrence","2026-06-12",{"date":181,"type":38},"2026-06-15",{"date":183,"type":38},"2024-06-11",{"date":185,"type":22},"2029-03",{"name":187,"class":162},"University Hospital, Brest",13,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100616300","phase-4-statins-to-prevent-cancer-associated-blood-clots-100616300","NCT07303816","Statins to Prevent Cancer Associated Blood Clots","STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism","STAT-CAT","Inclusion Criteria:\n\n* age \\> 18 years with no contraindication to statin therapy and able to provide informed consent\n* newly diagnosed, newly recurrent or newly progressive malignancy with locally advanced\u002Fmetastatic disease initiating new systemic cancer therapy with no plan for prophylactic anticoagulation.\n* intermediate or high risk for cancer associated VTE based on the Khorana Score (KS) and modified Khorana Score (mKS) risk assessment tools (KS 2-4 or mKS 2-5).\n* ECOG performance status 0-2\n* Life expectancy \\> 6 months\n\nExclusion Criteria:\n\n* current use of statin therapy or known statin intolerance.\n* current use of systemic anticoagulation.\n* very low VTE risk defined by a Khorana Score (KS) of 0-1 and a modified Khorana Score (mKS) of 0-1.\n* extremely high VTE risk defined by a Khorana Score (KS) \\> 5 or modified Khorana Score (mKS) \\> 6 where guideline recommendations for systemic anticoagulation should be considered.\n* Basal cell or squamous cell carcinoma in situ cancers of the skin as the sole qualifying cancer type\n* ineligible cancer types where level of acuity is likely to preclude trial participation (including acute leukemia, myelodysplastic syndromes, primary brain tumors, primary CNS lymphoma, or plans to undergo hematopoietic stem cell transplantation or CAR-T cell therapy). (g) Known ALT, AST, or creatine kinase (CK) levels \\> 3 x ULN; eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2, or Child Pugh Class B or C liver disease\n* Known hepatitis C or HIV disease, or intent to use certain oncologic agents (daralutemide, regorafenib, and cabozantinib) or some antivirals used to treat hepatitis C or HIV disease (combinations of sofosbuvir, velpatasvir, and voxilaprevir) which can significantly increase rosuvastatin exposure and potentially lead to drug-drug interactions (DDIs).\n* Conditions that, in the opinion of the investigator, would compromise the well-being of the subject or conduct of the study, including as examples life expectancy less than 6 months or an ECOG Performance Status \\> 3.",{"count":198,"type":22},4000,[200],"PHASE4","Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage.\n\nThe primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.",[28,203,204],"Cancer","Cardiovascular Events",[206,207,208,209,210,211],"statin","pulmonary embolism","rosuvastatin","cancer","venous thromboembolism","prophylactic anticoagulation","2026-06-11",{"date":179,"type":38},{"date":212,"type":38},{"date":216,"type":22},"2032-03-31",{"name":218,"class":162},"Brigham and Women's Hospital",2,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":163},"100495779","phase-4-thromboprophylaxis-in-individuals-undergoing-superficial-endovenous-treatment-thrive-100495779","NCT05735639","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial","THRIVE","Inclusion Criteria:\n\n* Adults (\\>18 years)\n* Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia\n* Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue\n\nExclusion Criteria:\n\n* Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation\n* Previous personal or first-degree relative history of VTE\n* Thrombophilia\n* Female patients of childbearing potential who have a positive pregnancy test\n* A history of allergy to heparins or direct oral anticoagulants\n* A history of heparin-induced thrombocytopenia\n* Inherited and acquired bleeding disorders\n* Evidence of active bleeding\n* Concomitant major health problems such as active cancer and chronic renal and\u002For liver impairment\n* Known thrombocytopenia (platelets known to be less than 50 x 109\n\n  \u002Fl)\n* Surgery or major trauma in the previous 90 days\n* Recent ischemic stroke in the previous 90 days\n* Inability to provide consent",{"count":229,"type":22},3175,[200],"Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.\n\nVaricose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.\n\nThis study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.",[28,233],"Varicose Veins","2026-06-03",{"date":236,"type":38},"2026-06-04",{"date":238,"type":38},"2024-01-22",{"date":240,"type":22},"2027-12-31",{"name":242,"class":162},"Imperial College London",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":253,"briefSummary":254,"conditions":255,"keywords":263,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700","NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial",{"count":252,"type":22},276,[200],"The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[61,256,257,258,259,260,28,261,262],"Embolism","Embolism and Thrombosis","Lung Diseases","Cardiovascular Diseases","Respiratory Tract Diseases","Anticoagulant-induced Bleeding","Bleeding",[264],"subsegmental pulmonary embolism","2026-05-20",{"date":267,"type":38},"2026-05-22",{"date":269,"type":38},"2020-05-15",{"date":271,"type":22},"2028-05",{"name":273,"class":162},"Drahomir Aujesky",40,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":285,"conditions":286,"keywords":287,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":163},"100637111","strategy-pe-real-world-treatment-strategies-for-intermediate-high-risk-pulmonary-embolism-100637111","NCT07603700","STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism","Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study","STRATEGY-PE","Inclusion Criteria:\n\n* Age unlimited (reflecting real-world population).\n* Symptom duration of acute PE ≤ 14 days.\n* Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.\n* Defined as Intermediate-High Risk PE meeting all of the following:\n* RV\u002FLV ratio ≥ 0.9 (by CT or Echocardiography).\n* Elevated cardiac biomarkers (Troponin \\> 99th percentile or BNP \\> 100 pg\u002FmL).\n* Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).\n* Able to provide informed consent and complete follow-up.\n\nExclusion Criteria:\n\n* Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.\n* Unable to obtain baseline or follow-up CTPA imaging.\n* (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).",{"count":284,"type":22},1300,"This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.",[61,28],[288,289,32,290],"Acute Pulmonary Embolism","Intermediate-High Risk","Thrombolysis","2026-05-17",{"date":267,"type":38},{"date":294,"type":22},"2026-06-01",{"date":296,"type":22},"2029-12-31",{"name":298,"class":162},"Nanjing First Hospital, Nanjing Medical University",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100608012","prediction-of-venous-thrombosis-during-chemotherapy-the-pinpoint-study-100608012","NCT07196020","Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study","Prediction and Prevention of Venous Thrombo-embolism(VTE) During Chemotherapy Using Serial Determination of Haemostasis Biomarkers.","PINPOINT","Inclusion Criteria:\n\n* Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy\n* Patients who are over 18 years of age\n* Patients who are able to give full and informed written consent\n\nExclusion Criteria:\n\n* Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation \\> 3 months previously)\n* Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years\n* Familial bleeding diathesis\n* Known diagnosis of disseminated intravascular coagulation.\n* Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy)\n* Chemotherapy or immunotherapy 4 weeks before first baseline sample\n* Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point.",{"count":308,"type":22},380,"Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others. These clots can be prevented by using blood thinners (known as anticoagulants) but these are not suitable for everyone as they also carry a risk of bleeding. This study aims to identify which chemotherapy patients are most at risk of a blood clot and at what point in their treatment this is likely to happen. In this project biomarkers in the blood that are involved in blood clotting will be measured in cancer patients at four stages during chemotherapy to see how the biomarkers change during treatment. The blood samples for these tests are taken at the same time as the normal routine blood tests done before a chemotherapy cycle. Biomarker levels will be compared between those patients who subsequently get a VTE and those who do not get a VTE. This will help develop a biomarker based blood test to predict clots during chemotherapy. The biomarker based test will also be compared with other methods of predicting VTE in cancer patients which are currently in use. In the future, this blood test might be used to see if patients are at high risk of a clot during chemotherapy and provide a method to optimise the use of preventative anticoagulants in cancer patients during chemotherapy.",[28,203],[312,203,313,314,315],"Chemotherapy","Thrombin","Venous thromboembolism","Neoplasms","2026-05-14",{"date":318,"type":38},"2026-05-15",{"date":320,"type":38},"2025-10-01",{"date":322,"type":22},"2029-09-01",{"name":324,"class":162},"University of Dublin, Trinity College",3,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":349},"100623695","using-a-blood-test-and-software-tool-to-guide-treatment-for-venous-thromboembolism-100623695","NCT07399977","Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism","A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism","Inclusion Criteria:\n\n* Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental\u002Funsuspected proximal lower-limb DVT, symptomatic pulmonary embolism \\[PE\\] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).\n\nDiagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.\n\nDiagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.\n\n* Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):\n\n  * breast cancer regardless of cytotoxic-chemotherapy status\n  * hepatobiliary cancer regardless of cytotoxic-chemotherapy status\n  * prostate cancer regardless of cytotoxic-chemotherapy status\n  * non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days\n  * pancreatic cancer with cytotoxic-chemotherapy received within 30 days\n  * bladder cancer with cytotoxic-chemotherapy received within 30 days\n* Signed and dated informed consent by study participant\u002FLegally Authorized Representative (LAR).\n\nExclusion Criteria:\n\n* Contraindication to ongoing anticoagulation\n* Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)\n* History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and\u002For symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol\u002FL (2 g\u002FdL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).\n* Known diagnosis of disseminated intravascular coagulation (DIC)\n* Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE\n* Enrolled in hospice care\n* Currently has inferior vena cava (IVC) filter\n* Diagnosis of an active hematologic malignancy",{"count":334,"type":22},259,[25],"The purpose of this study is to find out whether a software tool, ctDNA\u002FVTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.",[28,29],[28,29,339,340],"25-095","Memorial Sloan Kettering Cancer Center","2026-05-04",{"date":343,"type":38},"2026-05-05",{"date":345,"type":38},"2026-01-30",{"date":347,"type":22},"2030-01-30",{"name":340,"class":162},8,{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":356,"targetDuration":358,"studyType":57,"phases":4,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":372},"100589152","development-and-application-of-a-thrombosis-risk-prediction-model-in-lung-cancer-patients-treated-with-immune-checkpoint-inhibitors-100589152","NCT06950697","Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Age ≥18 years\n* Histopathologically confirmed lung cancer diagnosis at enrollment\n* Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of two or more primary cancers\n* Missing data for key variables\n* Inability to comply with follow-up requirements\n* Presence of VTE\u002FATE at the time of ICI initiation",{"count":357,"type":22},2400,"30 Months","The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are:\n\n1. What is the real-world incidence of VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n2. What are the risk factors and biomarkers for VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n3. What is the impact of VTE\u002FATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors?\n\nResearchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE\u002FATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.",[361,28,60,362],"Lung Cancer","Immune Checkpoint Inhibitors (ICIs)","2026-04-26",{"date":365,"type":38},"2026-04-30",{"date":367,"type":38},"2019-01-01",{"date":369,"type":22},"2027-12-01",{"name":371,"class":162},"Beijing Chao Yang Hospital",5,{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":397},"100631883","intermediate-versus-standard-dose-enoxaparin-to-prevent-venous-thromboembolism-in-severe-trauma-patients-a-multicenter-double-blind-randomised-controlled-trial-100631883","NCT07506473","Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial","HEPTRAUMA","Inclusion Criteria:\n\n* All adult patients (age ≥18 years) admitted to an intensive care unit following trauma with an expected stay \\>48 hours and a planned administration of LMWH.\n* Affiliation to the French social security system or European (CEAM)\n\nExclusion Criteria:\n\n* Prehospital cardiac arrest\n* Hospital admission \\>72 hours\n* More than one dose of prophylactic anticoagulant already administered since trauma\n* Renal failure defined by creatinine clearance of 30 mL\u002Fmin or less (Cockcroft-Gault formula)\n* Body weight \\>100 kg or \\\u003C45 kg\n* Indication for therapeutic anticoagulation\n* Major known thrombophilia (e.g. antiphospholipid syndrome, antithrombin deficiency)\n* Constitutional bleeding disorder (haemophilia, von Willebrand disease, coagulation factor deficiency, platelet disorder).\n* Thrombocytopenia inferior to 50 G.L-1\n* History of heparin-induced thrombocytopenia\n* Study drug hypersensitivity\n* Limitation of life support, life expectancy ≤7 days or palliative care\n* Contraindication to the administration of anticoagulant according to the SPC (Active clinically significant bleeding or a condition associated with a high risk of bleeding, such as a recent haemorrhagic stroke, gastrointestinal ulcer, the presence of a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmological surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intrarachid or intracerebral vascular anomalies.)\n* pregnant or breastfeeding woman\n* Inclusion in another experimental trial\n* Protected person (art. L1121-5 to L1121-8 of the CSP or art. 31 to 35 of European regulation 536\u002F2014)",{"count":381,"type":22},540,[25],"Venous thromboembolism is a frequent issue in severe trauma patients. Guidelines for venous thromboembolism prevention include the use of pharmacological thromboprophylaxis, mainly with low-molecular-weight heparin, and\u002For mechanical thromboprophylaxis. However, a high incidence of venous thromboembolism is observed despite standard dose thromboprophylaxis (such as enoxaparin 40 mg once daily).\n\nAn increase of the dose of anticoagulants could improve thromboprophylaxis in trauma patients. To date, two randomised trials have assessed the effect of weight-based low-molecular-weight heparin dosing vs. fixed dose in trauma patients. These pilot studies did not demonstrate a statistical difference between groups although there was a trend in favour of a lower incidence of deep vein thromboses with the increased dose low-molecular-weight heparin prophylaxis. However, both studies included non-severe trauma patients and the second study focused only on deep vein thromboses. Other studies suggested that a superior-than-standard dose of low-molecular-weight heparin, sometimes\n\nguided by the anti-Xa activity, decreases the incidence of venous thromboembolism in severe trauma without increasing bleeding events, but they were observational in nature.\n\nThe hypothesis of the HEPTRAUMA trial is that, in severe trauma patients, a thromboprophylaxis with intermediate dose low-molecular-weight heparin (twice the standard dose) decreases the incidence of major venous thromboembolism compared to standard dose.",[385,28],"Severe Trauma Patient",[94,387,388],"Severe trauma","Anticoagulant","2026-04-23",{"date":391,"type":38},"2026-04-29",{"date":393,"type":22},"2026-04",{"date":271,"type":22},{"name":396,"class":162},"University Hospital, Grenoble",17,{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":163},"100487524","evaluation-of-the-scaled-scaling-acceptable-cds-100487524","NCT05628207","Evaluation of the SCALED (SCaling AcceptabLE cDs)","Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention - CDS Data","Inclusion Criteria:\n\n* age 18 and older\n* admitted with a TBI\n\nExclusion Criteria:\n\n* Patients who die within 24 hours of hospital admission and patients documented as \"comfort cares\" during the first 72 hours of hospitalization or with mild TBI will be excluded from final analysis.",{"count":406,"type":22},15000,"This project will adapt a currently deployed Clinical Decision Support (CDS) system to deliver a VTE prevention guideline for adult patients with traumatic brain injury (TBI). We believe this is an ideal PCOR use case given PCORI's continued effort to combat VTE in trauma and our experience previously implementing this guideline. The Our overall goal is to successfully scale, evaluate, and maintain an interoperable TBI CDS across 7 total institutions.",[409,28],"Traumatic Brain Injury",{"date":411,"type":38},"2026-04-24",{"date":413,"type":38},"2023-05-16",{"date":415,"type":22},"2026-07-31",{"name":417,"class":162},"University of Minnesota",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":425,"targetDuration":427,"studyType":57,"phases":4,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":442},"100507008","post-market-celect-platinum-vena-cava-filter-and-gunther-tulip-retrieval-set-study-100507008","NCT05881798","Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study","Post-Market Celect Platinum Vena Cava Filter and Günther Tulip Retrieval Set Study","Inclusion Criteria:\n\n* A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed\n* Subject has not previously participated in the Cook MDR-2126 study.\n\nExclusion Criteria:\n\n* Patients will be excluded from enrollment if the patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data or is not willing to sign the Informed Consent.",{"count":426,"type":22},82,"5 Years","This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.",[92,28,61],[431,432],"Celect Platinum Vena Cava Filter","Gunther Tulip Vena Cava Filter Retrieval Set","2026-04-14",{"date":435,"type":38},"2026-04-17",{"date":437,"type":38},"2025-06-02",{"date":439,"type":22},"2030-12",{"name":441,"class":45},"Cook Research Incorporated",7,{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":468},"100631360","pulmonary-embolism-in-patients-with-acute-heart-failure-pehf-study-100631360","NCT07499661","Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)","Pulmonary Embolism in Patients With Acute Heart Failure: A Pragmatic Cluster-Randomized Trial (PEHF Study)","PEHF","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Admission to the emergency department or cardiology unit of a participating center\n* Recent onset or worsening dyspnea and\u002For orthopnea\n* Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following:\n\n  * Bilateral pulmonary crackles on auscultation and\u002For peripheral edema\n  * Signs of pulmonary congestion on chest X-ray or lung\u002Fcardiac ultrasound\n  * Elevated natriuretic peptide levels (BNP or NT-proBNP)\n  * Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure)\n* Patient affiliated with or beneficiary of a social security system\n* Patient able and willing to provide free, informed, and written consent\n\nExclusion Criteria:\n\n* Shock state suggesting cardiogenic shock and\u002For severe pulmonary embolism\n* Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations\n* Evidence of acute coronary syndrome on electrocardiogram at admission\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Known hypersensitivity or allergy to iodinated contrast agents\n* Ongoing therapeutic anticoagulation for more than 48 hours prior to admission\n* Hospitalization for more than 48 hours prior to inclusion\n* Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable)\n* Inadequate understanding of the French language preventing proper study information and consent\n* Pregnant, breastfeeding, or postpartum women\n* Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)",{"count":452,"type":22},740,[25],"This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it.\n\nDoctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot.\n\nHowever, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart failure who die may actually have had an undiagnosed pulmonary embolism. Current medical guidelines recommend checking for pulmonary embolism when the cause of breathing problems is unclear, but in real-life practice, this is not always done.\n\nThe goal of this study is to find out whether pulmonary embolism is underdiagnosed in patients with suspected acute heart failure and whether systematically testing for it could improve patient outcomes.\n\nTo do this, the study will compare two approaches in several hospitals. In half of the hospitals, doctors will follow their usual practice and decide case by case whether to test for pulmonary embolism. In the other half, doctors will systematically test all eligible patients for pulmonary embolism using recommended diagnostic methods.\n\nAdult patients admitted with recent or worsening breathing difficulties and signs of acute heart failure may be included in the study, provided they give their consent. Researchers will collect information about their symptoms, tests, diagnosis, and treatments.\n\nPatients will be monitored during their hospital stay and for three months afterward. The study will track important outcomes such as survival, new blood clots, bleeding events, repeated hospital visits for breathing problems, and overall time spent in the hospital.\n\nThe researchers expect to include about 740 patients in total. They estimate that pulmonary embolism may be found in about 1% of patients with usual care, but up to 5% when doctors systematically look for it.\n\nThis study aims to better understand how often pulmonary embolism occurs in patients with acute heart failure and whether more systematic testing could lead to earlier diagnosis and better care. The results could help improve medical practice and reduce complications or deaths related to missed diagnoses.",[456,457,28],"Acute Heart Failure (AHF)","Pulmonary Embolism (Diagnosis)",[459],"Cluster-randomized trial","2026-03-30",{"date":462,"type":38},"2026-04-03",{"date":464,"type":22},"2026-06",{"date":466,"type":22},"2028-09",{"name":111,"class":112},10,{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":325},"100528881","grace-evaluating-compression-stockings-in-patients-that-require-extended-duration-pharmacological-thromboprophylaxis-100528881","NCT06166537","GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis","Graduated Compression Stocking as an Adjunct to Extended Duration Pharmacological Thromboprophylaxis for Venous Thromboembolism Prevention","GRACE","Inclusion Criteria:\n\n* Adults (≥18 years of age)\n* Participants undergoing elective surgery; risk assessed as requiring EDPTP\n\nExclusion Criteria:\n\n* Contraindications to EDPTP or GCS\n* Individuals requiring therapeutic anticoagulation e.g., anticoagulation for previous DVT\n* Known thrombophilia or thrombogenic disorder",{"count":478,"type":22},8608,[25],"Individuals attending the hospital to undergo operations are at risk of developing blood clots in the legs, known as deep vein thrombosis (DVT). A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lungs' ability to move oxygen from the air into the blood and may be life-threatening. This is known as pulmonary embolism (PE). DVT and PE are known collectively as venous thromboembolism or VTE.\n\nThe importance of preventing VTE in surgical patients is widely recognised, with two main strategies used: thinning the blood with regular injections and\u002For tablets and wearing elastic stockings to help stop blood from sitting in the leg veins where it can clot.\n\nEvidence for using elastic stockings to prevent VTE has recently been challenged. Additionally, there is a lack of evidence for the additional benefit of stockings over and above that of blood thinning medications. If stockings were to reduce VTE over and above blood thinning medication, these benefits need to be weighed against the risks and disadvantages of stockings, including discomfort, restricting blood flow to the leg causing blisters and wounds in addition to the cost. If stockings were found not to reduce the risk of clots, they would no longer need to be used in these patients, thus reducing the disadvantages of stockings, and saving the NHS millions of pounds per year.\n\nCertain types of operations (300,000 per year in the UK) are linked with a particularly high risk of VTE, including cancer surgery, surgery in the abdomen and pelvis, and bone (orthopaedic) surgery. In these cases, patients are offered blood thinning medications both during their hospital stay and for a period after they have left the hospital. Furthermore, these patients are offered stockings to wear while in the hospital.\n\nIt is not known if, in patients who receive blood thinning medications both in hospital and after discharge, the addition of wearing stockings whilst in hospital reduces their risk of VTE any further.\n\nThe purpose of this study is to investigate if it is worthwhile using stockings, in addition to blood thinning medication, to reduce blood clots after surgery. People enrolled in the study will be those at the highest risk of VTE and require an extended period of medication to reduce the risk of a blood clot.\n\nA computer will randomly choose one of the below treatments by chance to make the trial fair:\n\nA) Extended duration clot-reducing medicine in addition to stockings B) Extended duration clot-reducing medicine alone\n\nThe surgery and all the other medical care will continue as normal. Everyone in the study will get an ultrasound scan at 21 - 35 days after their operation to check if they have developed a blood clot. This is an additional scan, not routinely performed in the NHS, to make sure that all blood clots are detected at an early stage. Participants will receive a phone call at 7, 21-35 and 90 days after their treatment to see if they have developed a blood clot or had any problems with the treatment.",[28,482],"Surgery","2026-03-24",{"date":485,"type":38},"2026-03-25",{"date":487,"type":38},"2024-04-27",{"date":489,"type":22},"2027-03-31",{"name":242,"class":162},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":163},"100574015","timing-of-venous-thromboembolism-prophylaxis-in-patients-with-hypertensive-intracerebral-hemorrhage-100574015","NCT06753786","Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","Early or Delayed Initiation of Venous Thromboembolism Prophylaxis With Heparin in Patients With Hypertensive Intracerebral Hemorrhage","Inclusion Criteria:\n\n* the presence of hypertensive intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)\n* Being on an anticoagulant during preadmission period and on day of hospital admission\n* Death within the first 2 days after hospital admission\n* Detection of venous thromboembolism in a patient at the moment of hospital admission\n* Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin\n* The presence of a malignancy (cancer) in a patient at the moment of hospital admission",{"count":499,"type":22},200,[25],"The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral hemorrhage. The main questions it aims to answer are:\n\n* What is the optimal time for the beginning of anticoagulation with heparin to efficiently prevent venous thromboembolism in patients with hypertensive intracerebral hemorrhage? Early beginning (within the first 2 days but not earlier than 12 hours after the admission of a patient) or delayed beginning (on the third day after the admission of a patient)?\n* Which of the two timeframes (early or delayed) for anticoagulation beginning is the most safe in terms of bleeding complications including intracerebral hemorrhage expansion?\n\nResearchers will compare the results of early and delayed start of anticoagulation using heparin in patients with hypertensive intracerebral hemorrhage to define the optimal start time for anticoagulation that provides the most favourable efficiency\u002Fsafety profile.\n\nParticipants will:\n\n* Undergo a computed tomography (CT) scan of the brain on hospital admission and then 12-24 hours after the hospital admission and 24 hours after the beginning of venous thromboembolism prophylaxis using heparin;\n* Undergo the ultrasound examination of lower extremity deep veins on hospital admission and then once every 7 days;\n* Receive prophylactic doses of low molecular weight heparin or unfractionated heparin either beginning within the first 2 days but not earlier than 12 hours after the hospital admission or starting on the 3rd day after the hospital admission.",[28,61,503,92],"Intracerebral Hemorrhage",[505,506,507,314,508,32,509,510],"Prophylaxis","Deep vein thrombosis","Pulmonary embolism","Intracerebral hemorrhage","Low molecular weight heparin","Unfractionated heparin","2026-03-22",{"date":483,"type":38},{"date":514,"type":38},"2024-10-21",{"date":516,"type":22},"2028-12-31",{"name":518,"class":162},"Pirogov Russian National Research Medical University",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":526,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":163},"100385190","phase-2-optimal-dosing-for-low-dose-aspirin-chemoprophylaxis-for-vte-following-total-joint-arthroplasty-100385190","NCT04295486","Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty","Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.","Inclusion criteria:\n\n* \\> 18 years of age\n* Planning to undergo a primary total hip or knee arthroplasty\n\nExclusion Criteria:\n\n* High risk patients for VTE as defined by:\n\n  * History of venous thromboembolism\n  * Active malignancy\n  * Known pro thrombotic condition\n* BMI \\> 40\n* Patients requiring anticoagulation for pre-existing conditions\n* Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.\n* Patients not fluent in the language of the informed consent form\n* Prisoners\n* Pregnancy\n* Reported to have mental illness or belonging to a vulnerable population","19 Years",{"count":528,"type":22},5478,[530],"PHASE2","This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.",[28],[534,535,536],"Chemoprophylaxis","Hip Surgery","Knee Surgery","2026-03-09",{"date":539,"type":38},"2026-03-11",{"date":541,"type":38},"2021-03-01",{"date":543,"type":22},"2027-03-01",{"name":545,"class":162},"University of Miami",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":163},"100288981","caprini-score-in-venous-surgery-a-prospective-cohort-study-100288981","NCT03041805","Caprini Score in Venous Surgery: a Prospective Cohort Study","A Prospective Cohort Register Study for Validation of Caprini Score in Patients Undergoing Varicose Vein Surgery","CAPSIVS","Inclusion Criteria:\n\n* age over 18 years\n* any kind of varicose vein surgery\n* follow up for 4 weeks after the procedure\n* examination for VTE at 2-4 weeks after the procedure, including duplex ultrasound\n\nExclusion Criteria:\n\n\\- lost for follow-up during 4 weeks",{"count":555,"type":22},3000,"The aim of the study is to make a validation of Caprini score in patients undergoing varicose veins surgery, especially endovascular procedures (endovascular laser treatment - EVLT, radiofrequency ablation - RFA, ultrasound-guided foam sclerotherapy - USFS) and to identify patients with elevated risk of postoperative venous thromboembolism (VTE) who will benefit from prophylactic anticoagulation.",[28,233],[210,559,207,560,561,562,563,564,565,566],"deep vein thrombosis","varicose veins","surgery","endovenous laser treatment","radiofrequency ablation","ultrasound-guided foam sclerotherapy","register","anticoagulation","2026-02-26",{"date":569,"type":38},"2026-03-02",{"date":571,"type":38},"2017-01-01",{"date":573,"type":22},"2027-01-01",{"name":518,"class":162},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":583,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":589,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":599,"locationsCount":163},"100341636","computerized-decision-support-for-prevention-of-vte-in-hospitalized-medical-patients-across-the-continuum-of-care-dc-ealert-100341636","NCT03728166","Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","Randomized Controlled Trial of Computerized Decision Support for Prevention of Venous Thromboembolism in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","DC-eALERT","Inclusion Criteria:\n\n-≥40 years of age, are hospitalized for acute medical illness (heart failure, respiratory failure, infectious disease, rheumatic disease, or ischemic stroke), have reduced mobility, are not prescribed thromboprophylaxis at hospital discharge, and have one additional risk factor for VTE:\n\n* Age ≥60\n* Prior VTE OR\n* History of cancer\n\nExclusion Criteria:\n\n\\- Prescribed thromboprophylaxis at hospital discharge","40 Years",{"count":585,"type":22},400,[25],"Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-duration enoxaparin. Obstacles to integration of these data in the hospitalized Medical Service patient population, including failure to identify at-risk patients, educational gaps in strategies for VTE prevention after discharge, and medication nonadherence, can be overcome with alert-based computerized decision support. This study is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness.\n\nSpecific Aim #1: To determine the impact of electronic alert-based CDS (EPIC Best Practice Advisory \\[BPA\\]) on prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.\n\nSpecific Aim #2: To estimate the impact of electronic alert-based CDS (EPIC BPA) on the frequency of symptomatic VTE in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.",[28],[210,590,591,592],"prevention","medical patients","hospital discharge","2026-02-24",{"date":595,"type":38},"2026-02-25",{"date":597,"type":38},"2019-02-01",{"date":35,"type":22},{"name":218,"class":162},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":145,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":163},"100438662","impact-of-covid-19-vaccines-on-cerebrovascular-health-100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",{"count":608,"type":22},500,"Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[611,612,613,614,615,616,617,618,60,28],"Stroke","Stroke, Acute","Stroke, Ischemic","Dementia","Brain Ischemia","Alzheimer Disease","Brain Diseases","Major Adverse Cardiovascular Event","2026-02-21",{"date":593,"type":38},{"date":622,"type":38},"2021-07-05",{"date":624,"type":22},"2026-12-31",{"name":626,"class":162},"Chinese University of Hong Kong",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":637,"briefSummary":638,"conditions":639,"keywords":642,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":325},"100582267","phase-3-the-effect-of-kinisoquin-on-thromboembolic-events-in-patients-with-metastatic-or-locally-advanced-pancreatic-cancer-100582267","NCT06861088","The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)","CATIQ P3","Inclusion Criteria:\n\n1. Participants must have histological or cytological confirmed pancreatic adenocarcinoma malignancy that is metastatic (including recurrent with distant metastases) or locally advanced.\n2. Receiving first line chemotherapy (within 45 days of first dose of study drug) Note: subjects must be either initiating first systemic cancer therapy regimen following initial diagnosis or initiating first cycle of chemotherapy for disease recurrence.\n3. Minimum age 18 years.\n4. Life expectancy of greater than 4 months.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n6. Participants must have preserved organ and marrow function as defined by:\n\n   * Platelet count ≥ 100,000\u002FmcL.\n   * Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5x institutional upper limit of normal (ULN).\n   * Total bilirubin ≤ 3x ULN without liver metastases and \\\u003C 5x ULN in presence of liver metastases.\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN without liver metastases and \\\u003C 5x ULN in the presence of liver metastases\n   * Estimated creatinine clearance (CrCl \\> 30 mL\u002Fmin).\n7. Willingness of women of child-bearing potential and men to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until at least 4 weeks after study completion.\n8. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Participants with known brain metastases\n2. Prior history of documented thromboembolic event within the last 12 months (excluding central line associated events whereby patients completed anticoagulation)\n3. Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)\n4. History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months\n5. Familial bleeding diathesis\n6. Known diagnosis of disseminated intravascular coagulation (DIC)\n7. Currently receiving anticoagulant therapy\n8. Current daily use of aspirin (\\> 100mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen \\> 800mg daily or equivalent)\n9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n10. Known intolerance to the active ingredient of Kinisoquin™, isoquercetin, nicotinic acid, or ascorbic acid (including known G6PD deficiency)\n11. Females of child-bearing potential who are lactating, have a positive pregnancy test at Screening, or are unwilling to use acceptable contraception prior to study entry and for the duration of study participation until at least 4 weeks after study completion.\n12. Participation in other clinical trials The study is open to any individual who has a metastatic or locally advanced pancreatic adenocarcinoma malignancy without discrimination based on race, religion, political affiliation, or other criteria.",{"count":636,"type":22},480,[89],"The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.",[28,640,641],"Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma",[640,643,64,644,92,61,645,646],"Pancreatic Adenocarcinoma","Cancer-associated Thrombosis","Chemotherapy-associated VTE","Locally Advanced Pancreatic Cancer","2026-01-29",{"date":649,"type":38},"2026-02-02",{"date":651,"type":38},"2025-12-19",{"date":653,"type":22},"2029-10-31",{"name":655,"class":45},"Quercis Pharma AG",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":23,"phases":664,"briefSummary":665,"conditions":666,"keywords":669,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":163},"100491797","phase-2-venous-thromboembolism-prevention-in-outpatients-with-glioma-100491797","NCT05683808","Venous Thromboembolism Prevention in Outpatients With Glioma","VTE-POG","Inclusion Criteria:\n\n* Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.\n* Age 18 and old\n* Karnofsky performance status (KPS) 60-100\n* Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.\n* Ability to provide informed consent.\n* Planning for treatment with radiation and chemotherapy.\n\nExclusion Criteria:\n\n* Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.\n* Pregnancy.\n* Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.\n* Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.\n* Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).\n* Estimated life expectancy of \\\u003C3 months.",{"count":274,"type":22},[530],"This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.",[667,668,28],"Glioblastoma","Astrocytoma",[670,667,668,314,671],"High grade glioma","Apixaban","2026-01-27",{"date":345,"type":38},{"date":675,"type":38},"2023-01-16",{"date":677,"type":22},"2027-06-30",{"name":679,"class":162},"University of Vermont Medical Center"]